Lurbinectedin is a medication used in the treatment of certain types of cancer, such as small cell lung cancer. There is no information available on the safety of lurbinectedin for breastfeeding mothers, and it is recommended that women do not breastfeed while taking this medication. According to the drug label, it is unknown if lurbinectedin is excreted in human milk, and the potential for serious adverse reactions in nursing infants cannot be ruled out. Therefore, it is recommended that women discontinue breastfeeding while taking lurbinectedin.

Sources:
[1] Drug Patent Watch. (n.d.). Lurbinectedin. Retrieved from https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] Oncology Nursing Society. (2021). Oncology drug reference sheet: Lurbinectedin. Retrieved from https://voice.ons.org/news-and-views/oncology-drug-reference-sheet-lurbinectedin
[3] Mayo Clinic. (2021). Lurbinectedin (Intravenous Route): Side Effects. Retrieved from https://www.mayoclinic.org/drugs-supplements/lurbinectedin-intravenous-route/side-effects/drg-20490804?p=1.